Cargando…

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer

In the past several years, immunotherapy has emerged as a viable treatment option for patients with advanced non‐small cell lung cancer (NSCLC) without actionable driver mutations that have progressed on standard chemotherapy. We are also beginning to understand the methods of immune evasion employe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Angel, Coffey, David G., Warren, Edus H., Ramnath, Nithya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055165/ https://www.ncbi.nlm.nih.gov/pubmed/27416962 http://dx.doi.org/10.1002/cam4.819

Ejemplares similares

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues
por: Fan, Teresa WM, et al.
Publicado: (2021)

Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
por: Kandasamy, Matheswaran, et al.
Publicado: (2023)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
por: Rezasoltani, Sama, et al.
Publicado: (2020)

Optimal cancer evasion in a dynamic immune microenvironment generates diverse post-escape tumor antigenicity profiles
por: George, Jason T, et al.
Publicado: (2023)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
por: Zhang, Zhuo, et al.
Publicado: (2015)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

The CD73 immune checkpoint promotes tumor cell metabolic fitness
por: Allard, David, et al.
Publicado: (2023)

TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells
por: Lan, Xinyan, et al.
Publicado: (2019)

The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion
por: Goy, Erwan, et al.
Publicado: (2022)

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Sun, Li‐Yue, et al.
Publicado: (2021)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
por: Carbone, Antonino, et al.
Publicado: (2019)

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
por: Coffey, David G., et al.
Publicado: (2022)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery
por: Sipe, Laura M, et al.
Publicado: (2022)

Ovarian cancer: Current status and strategies for improving therapeutic outcomes
por: Chandra, Ashwin, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
por: Schlick, Brian, et al.
Publicado: (2022)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
por: Mhanna, Laurent, et al.
Publicado: (2019)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects
por: Zhou, Zhi‐Rui, et al.
Publicado: (2018)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
por: Gurska, Lindsay, et al.
Publicado: (2023)

Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer
por: Purcell, Emma, et al.
Publicado: (2021)

Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
por: Ferdinandus, Justin, et al.
Publicado: (2021)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qt55n7l1nb8f8vqo1kc7f2qu39